<p><strong>Pregnancy</strong>: Irbesartan is contraindicated in the second and third trimesters of&nbsp;pregnancy. In the second and third trimesters, substances that act directly on the&nbsp;renin-angiotensin-system can cause foetal or neonatal renal failure, foetal skull&nbsp;hypoplasia and even foetal death. As precautionary measure, irbesartan should&nbsp;preferably not be used during first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy. If&nbsp;pregnancy is diagnosed, irbesartan should be discontinued as soon as possible, skull&nbsp;and renal function should be checked with echography if, inadvertently, the&nbsp;treatment was taken for a long period.<br />
<br />
<strong>Lactation</strong>: Irbesartan is contraindicated during lactation. It is not known whether&nbsp;irbesartan is excreted in human milk. Irbesartan is excreted in the milk of lactating&nbsp;rats. Precautions: Intravascular volume depletion: symptomatic hypotension,&nbsp;especially after the first dose, may occur in patients who are volume and/or sodium&nbsp;depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Irbesartan.</p>